Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

The development of an inline Raman spectroscopic analysis method as a quality control tool for hot melt extruded ramipril fixed-dose combination products.

Andrews GP, Jones DS, Senta-Loys Z, Almajaan A, Li S, Chevallier O, Elliot C, Healy AM, Kelleher JF, Madi AM, Gilvary GC, Tian Y.

Int J Pharm. 2019 Jul 20;566:476-487. doi: 10.1016/j.ijpharm.2019.05.029. Epub 2019 May 11.

PMID:
31085253
2.

Exploring the potential of neutron imaging for life sciences on IMAT.

Burca G, Nagella S, Clark T, Tasev D, Rahman IA, Garwood RJ, Spencer ART, Turner MJ, Kelleher JF.

J Microsc. 2018 Dec;272(3):242-247. doi: 10.1111/jmi.12761. Epub 2018 Oct 15.

PMID:
30320891
3.

A comparative study between hot-melt extrusion and spray-drying for the manufacture of anti-hypertension compatible monolithic fixed-dose combination products.

Kelleher JF, Gilvary GC, Madi AM, Jones DS, Li S, Tian Y, Almajaan A, Senta-Loys Z, Andrews GP, Healy AM.

Int J Pharm. 2018 Jul 10;545(1-2):183-196. doi: 10.1016/j.ijpharm.2018.05.008. Epub 2018 May 3.

PMID:
29730176
4.

A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors.

Zhao X, Pak E, Ornell KJ, Pazyra-Murphy MF, MacKenzie EL, Chadwick EJ, Ponomaryov T, Kelleher JF, Segal RA.

Cancer Discov. 2017 Dec;7(12):1436-1449. doi: 10.1158/2159-8290.CD-17-0281. Epub 2017 Sep 18.

5.

Sample environment for neutron scattering measurements of internal stresses in engineering materials in the temperature range of 6 K to 300 K.

Kirichek O, Timms JD, Kelleher JF, Down RB, Offer CD, Kabra S, Zhang SY.

Rev Sci Instrum. 2017 Feb;88(2):025103. doi: 10.1063/1.4974815.

PMID:
28249503
6.

RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.

Zhao X, Ponomaryov T, Ornell KJ, Zhou P, Dabral SK, Pak E, Li W, Atwood SX, Whitson RJ, Chang AL, Li J, Oro AE, Chan JA, Kelleher JF, Segal RA.

Cancer Res. 2015 Sep 1;75(17):3623-35. doi: 10.1158/0008-5472.CAN-14-2999-T. Epub 2015 Jun 30.

7.

Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39.

Bassilana F, Carlson A, DaSilva JA, Grosshans B, Vidal S, Beck V, Wilmeringwetter B, Llamas LA, Showalter TB, Rigollier P, Bourret A, Ramamurthy A, Wu X, Harbinski F, Plonsky S, Lee L, Ruffner H, Grandi P, Schirle M, Jenkins J, Sailer AW, Bouwmeester T, Porter JA, Myer V, Finan PM, Tallarico JA, Kelleher JF 3rd, Seuwen K, Jain RK, Luchansky SJ.

Nat Chem Biol. 2014 May;10(5):343-9. doi: 10.1038/nchembio.1481. Epub 2014 Mar 16.

PMID:
24633354
8.

Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.

Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, Tabak B, Beroukhim R, Wang Q, Zhao J, Dorsch M, Buonamici S, Ligon KL, Kelleher JF, Segal RA.

Nat Med. 2013 Nov;19(11):1518-23. doi: 10.1038/nm.3328. Epub 2013 Sep 29.

9.

Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened.

Peukert S, He F, Dai M, Zhang R, Sun Y, Miller-Moslin K, McEwan M, Lagu B, Wang K, Yusuff N, Bourret A, Ramamurthy A, Maniara W, Amaral A, Vattay A, Wang A, Guo R, Yuan J, Green J, Williams J, Buonamici S, Kelleher JF 3rd, Dorsch M.

ChemMedChem. 2013 Aug;8(8):1261-5. doi: 10.1002/cmdc.201300217. Epub 2013 Jul 2. No abstract available.

PMID:
23821351
10.

Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.

Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, Wu X, Pan S, Mickel L, Schuster C, Stary G, Jalili A, David OJ, Emotte C, Antunes AM, Rose K, Decker J, Carlson I, Gardner H, Stuetz A, Bertolino AP, Stingl G, De Rie MA.

J Invest Dermatol. 2011 Aug;131(8):1735-44. doi: 10.1038/jid.2011.48. Epub 2011 Mar 24.

11.

Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky SJ, Murtie J, Kelleher JF, Warmuth M, Sellers WR, Roberts CW, Dorsch M.

Nat Med. 2010 Dec;16(12):1429-33. doi: 10.1038/nm.2251. Epub 2010 Nov 14.

12.

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M.

Sci Transl Med. 2010 Sep 29;2(51):51ra70. doi: 10.1126/scitranslmed.3001599.

13.

Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.

Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, Han D, Liu J, Englund NP, Wang Y, Peukert S, Miller-Moslin K, Yuan J, Guo R, Matsumoto M, Vattay A, Jiang Y, Tsao J, Sun F, Pferdekamper AC, Dodd S, Tuntland T, Maniara W, Kelleher JF 3rd, Yao YM, Warmuth M, Williams J, Dorsch M.

ACS Med Chem Lett. 2010 Mar 16;1(3):130-4. doi: 10.1021/ml1000307. eCollection 2010 Jun 10.

14.

1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity.

Miller-Moslin K, Peukert S, Jain RK, McEwan MA, Karki R, Llamas L, Yusuff N, He F, Li Y, Sun Y, Dai M, Perez L, Michael W, Sheng T, Lei H, Zhang R, Williams J, Bourret A, Ramamurthy A, Yuan J, Guo R, Matsumoto M, Vattay A, Maniara W, Amaral A, Dorsch M, Kelleher JF 3rd.

J Med Chem. 2009 Jul 9;52(13):3954-68. doi: 10.1021/jm900309j.

PMID:
19469545
15.

Identification and structure-activity relationships of ortho-biphenyl carboxamides as potent Smoothened antagonists inhibiting the Hedgehog signaling pathway.

Peukert S, Jain RK, Geisser A, Sun Y, Zhang R, Bourret A, Carlson A, Dasilva J, Ramamurthy A, Kelleher JF.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):328-31. doi: 10.1016/j.bmcl.2008.11.096. Epub 2008 Dec 3.

PMID:
19091559
16.

Essential role of stromally induced hedgehog signaling in B-cell malignancies.

Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, Schultz P, Warmuth M.

Nat Med. 2007 Aug;13(8):944-51. Epub 2007 Jul 15.

PMID:
17632527
17.

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, Yanofsky R, Hutchinson R, Heerema NA, Nachman J, Blake M, Wells LM, Sorrell AD, Masterson M, Kelleher JF, Stork LC; Children's Oncology Group.

Blood. 2006 Aug 15;108(4):1165-73. Epub 2006 Apr 11.

18.

Bilateral breast relapse in acute myelogenous leukemia.

Monteleone PM, Steele DA, King AK, Konefal S, Kelleher JF.

J Pediatr Hematol Oncol. 2001 Feb;23(2):126-9. Review.

PMID:
11216705
19.

Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia.

Kelleher JF, Monteleone PM, Steele DA, Gang DL, Angelides AG.

J Pediatr Hematol Oncol. 2001 Feb;23(2):117-21.

PMID:
11216703
20.

Successful treatment of disseminated relapsed medulloblastoma in an infant by primary radiotherapy.

Narendran A, Monteleone PM, Steele DA, Hicks RJ, Kelleher JF.

J Pediatr Hematol Oncol. 2001 Jan;23(1):51-3.

PMID:
11196271
21.

Myosin VI is required for asymmetric segregation of cellular components during C. elegans spermatogenesis.

Kelleher JF, Mandell MA, Moulder G, Hill KL, L'Hernault SW, Barstead R, Titus MA.

Curr Biol. 2000 Nov 30;10(23):1489-96.

22.

Anti-D immunoglobulin in children with newly diagnosed immune thrombocytopenic purpura: a pilot study.

Monteleone PM, Vander Heyden MA, Steele DA, Kelleher JF.

Haematologica. 2000 Aug;85(8):887-8. No abstract available.

23.

Purification and assay of the Arp2/3 complex from Acanthamoeba castellanii.

Kelleher JF, Mullins RD, Pollard TD.

Methods Enzymol. 1998;298:42-51. No abstract available.

PMID:
9751870
24.

Intracellular motility: how can we all work together?

Kelleher JF, Titus MA.

Curr Biol. 1998 May 21;8(11):R394-7. Review.

25.

Arp2/3 complex from Acanthamoeba binds profilin and cross-links actin filaments.

Mullins RD, Kelleher JF, Xu J, Pollard TD.

Mol Biol Cell. 1998 Apr;9(4):841-52.

26.

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.

Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH.

J Clin Oncol. 1997 Aug;15(8):2780-5.

PMID:
9256119
27.

Actin' like actin?

Mullins RD, Kelleher JF, Pollard TD.

Trends Cell Biol. 1996 Jun;6(6):208-12.

PMID:
15157457
28.

Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.

Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL.

J Clin Oncol. 1996 May;14(5):1526-31.

PMID:
8622067
29.

Abscisic Acid-Induced Phosphoinositide Turnover in Guard Cell Protoplasts of Vicia faba.

Lee Y, Choi YB, Suh S, Lee J, Assmann SM, Joe CO, Kelleher JF, Crain RC.

Plant Physiol. 1996 Mar;110(3):987-996.

30.
31.

Prevalence of antibodies to hepatitis C virus in transfused children with cancer.

Monteleone PM, Andrzejewski C, Kelleher JF.

Am J Pediatr Hematol Oncol. 1994 Nov;16(4):309-13.

PMID:
7978047
32.

When to give platelet transfusions.

Kelleher JF.

Blood. 1993 Jul 15;82(2):682; author reply 683. No abstract available.

PMID:
8329722
33.

Recent developments in pulse oximetry.

Severinghaus JW, Kelleher JF.

Anesthesiology. 1992 Jun;76(6):1018-38. Review. No abstract available.

PMID:
1599088
34.

Treatment of iron-deficiency anemia complicated by scurvy and folic acid deficiency.

Clark NG, Sheard NF, Kelleher JF.

Nutr Rev. 1992 May;50(5):134-7.

PMID:
1630718
35.

Use of the automated differential leukocyte count in pediatric oncology.

Kelleher JF, Janik DL.

J Pediatr. 1991 Apr;118(4 Pt 1):578-80. No abstract available.

PMID:
2007936
36.

Iron deficiency in adolescent girls. Are athletes at increased risk?

Rowland TW, Stagg L, Kelleher JF.

J Adolesc Health. 1991 Jan;12(1):22-5.

PMID:
2007148
37.

Monosomy 7 syndrome in an infant with neurofibromatosis.

Kelleher JF, Carbone TV.

Am J Pediatr Hematol Oncol. 1991 Fall;13(3):338-41. Review.

PMID:
1793161
38.

Histiocytosis X of the vulva: a case report and review of the literature.

Otis CN, Fischer RA, Johnson N, Kelleher JF, Powell JL.

Obstet Gynecol. 1990 Mar;75(3 Pt 2):555-8. Review.

PMID:
2406669
39.
40.

The penumbra effect: vasomotion-dependent pulse oximeter artifact due to probe malposition.

Kelleher JF, Ruff RH.

Anesthesiology. 1989 Nov;71(5):787-91. No abstract available.

PMID:
2817477
41.

A different sort of diagnosis.

Kelleher JF.

South Med J. 1989 Apr;82(4):496-8. No abstract available.

PMID:
2649998
42.

Iron deficiency in athletes. Insights from high school swimmers.

Rowland TW, Kelleher JF.

Am J Dis Child. 1989 Feb;143(2):197-200.

PMID:
2916491
43.

Pulse oximetry.

Kelleher JF.

J Clin Monit. 1989 Jan;5(1):37-62. Review.

PMID:
2647912
44.

The effect of iron therapy on the exercise capacity of nonanemic iron-deficient adolescent runners.

Rowland TW, Deisroth MB, Green GM, Kelleher JF.

Am J Dis Child. 1988 Feb;142(2):165-9.

PMID:
3341317
45.

Serum testosterone response to training in adolescent runners.

Rowland TW, Morris AH, Kelleher JF, Haag BL, Reiter EO.

Am J Dis Child. 1987 Aug;141(8):881-3. No abstract available.

PMID:
3631020
46.

Iron deficiency in adolescent endurance athletes.

Rowland TW, Black SA, Kelleher JF.

J Adolesc Health Care. 1987 Jul;8(4):322-6.

PMID:
3610736
47.

Selection of replacement therapy for patients with severe factor VII deficiency.

Kelleher JF Jr, Gomperts E, Davis W, Steingart R, Miller R, Bessette J.

Am J Pediatr Hematol Oncol. 1986 Winter;8(4):318-23.

PMID:
3799932
48.

Oxygen binding and stability properties of Hb Santa Ana (beta 88 Leu----Pro).

Tanaka Y, Kelleher JF Jr, Schwartz E, Asakura T, Shelton J, Shelton JR, Schroeder WA.

Hemoglobin. 1985;9(2):157-69.

PMID:
3839771
49.

Inverse correlation between age related abnormalities of T-cell immunity and circulating thymosin alpha 1 levels in haemophilia A.

Kessler CM, Schulof RS, Alabaster O, Goldstein AL, Naylor PH, Phillips TM, Luban NL, Kelleher JF, Reaman GH.

Br J Haematol. 1984 Oct;58(2):325-36.

PMID:
6236839
50.

Changes in coagulation parameters with exercise in patients with classic hemophilia.

Koch B, Luban NL, Galioto FM Jr, Rick ME, Goldstein D, Kelleher JF Jr.

Am J Hematol. 1984 Apr;16(3):227-33.

PMID:
6424436

Supplemental Content

Loading ...
Support Center